High-dose injection provided the greatest benefit to survival in the Ndufs4 KO model while oral rapamycin at 378 PPM had the strongest impact on developmental weight gain (Figures 3C,D); the bolus provided by injection provides an enhanced benefit over steady dietary delivery in the mitochondrial disease model, perhaps by overcoming blood-brain barrier. The gene discussed is NDUFS4; the disease is inborn mitochondrial metabolism disorder.